Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.

The poster, entitled “A Phase 1 study of IPI-926, an inhibitor of the Hedgehog pathway, in patients with advanced or metastatic solid tumors,” will be presented by Antonio Jimeno, M.D., Ph.D., Associate Professor, University of Colorado School of Medicine, during the Developmental Therapeutics session, which will take place from 12:30 – 3:30 p.m. CEST (6:30 – 9:30 a.m. EDT) on Sunday, October 10, 2010 in Yellow Hall 1.

A copy of the poster will be available on Infinity’s website, www.infi.com, following its presentation.

Source : Infinity Pharmaceuticals, Inc.